AHCO
AdaptHealth Corp.
AHCO lost money over the past year, so it has no meaningful PE right now. Analysts expect a turn to a loss, though they disagree widely on how much.
AHCO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Under pressure |
AHCO's revenue, profitability, cash flow and balance sheet are all currently under pressure.
AHCO PE Valuation
AHCO has no meaningful PE right now: it lost money over the past year.
AHCO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect AHCO's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
AHCO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.97 | -630% |
| Q2 2026 | -$1.68 | -405% |
| Q1 2026 | -$0.59 | -202% |
| Q4 2025 | -$0.52 | -185% |
| Q3 2025 | $0.56 | +$2.21 |
| Q2 2025 | $0.55 | +$5.78 |
| Q1 2025 | $0.58 | +$5.85 |
| Q4 2024 | $0.61 | +$5.92 |
AHCO has swung to a loss: it lost $2.97 per share over the past year, after a profit the year before.
AHCO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $745.6M | -9.1% |
| Q2 2026 | $740.3M | -7.5% |
| Q1 2026 | $819.8M | +5.4% |
| Q4 2025 | $846.3M | -1.2% |
| Q3 2025 | $820.3M | +1.8% |
| Q2 2025 | $800.4M | -0.7% |
| Q1 2025 | $777.9M | -1.8% |
| Q4 2024 | $856.6M | -0.2% |
AHCO's revenue grew through 2022 and has held roughly level since: $746M last quarter, down 9.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -21% | -28 points |
| Q2 2026 | -19% | -29 points |
| Q1 2026 | 0.7% | -2.3 points |
| Q4 2025 | -8.7% | -20 points |
| Q3 2025 | 7.5% | -0.3 points |
| Q2 2025 | 9.9% | +3.4 points |
| Q1 2025 | 3% | -3.4 points |
| Q4 2024 | 11% | +37 points |
AHCO's operating margin was −21% last quarter, down 28 points from the same quarter a year ago, near the bottom of its range since 2020.
AHCO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $51.1M | -24% |
| Q2 2026 | -$20.9M | -129% |
| Q1 2026 | -$27.5M | -$27.4M |
| Q4 2025 | $79.3M | +8.5% |
| Q3 2025 | $66.8M | -21% |
| Q2 2025 | $73.3M | -37% |
| Q1 2025 | -$58K | +$38.8M |
| Q4 2024 | $73.1M | +9.7% |
AHCO still generates free cash flow, though less than at its 2024 peak: $82M over the past year.
AHCO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 3.8x | Elevated |
| Q4 2025 | 3.5x | Elevated |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.8x | Moderate |
| Q1 2025 | 3.2x | Elevated |
| Q4 2024 | 3.0x | Moderate |
| Q3 2024 | 6.1x | High |
| Q3 2023 | 54.3x | High |
AHCO's net debt is about 3.8 years of its operating earnings (EBITDA), up from 3.2 years a year ago.
AHCO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.5 | Neutral |
| Stochastic | 47.7 | Neutral |
AHCO's weekly RSI is 51 (neutral) and its Stochastic is 48 (neutral).
AHCO PE vs Healthcare Sector
| Metric | AHCO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AHCO has no meaningful PE right now: it lost money over the past year.
AHCO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.29 | 25% above |
| 20 week MA | $7.25 | 8.6% above |
| 50 week MA | $9.26 | 15% below |
| 100 week MA | $9.31 | 15% below |
| 200 week MA | $10.1 | 22% below |
AHCO has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 22% below its 200-week average.
AHCO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.7 | $37.9 | +256% |
| 2021 | $37.9 | $23.7 | -37% |
| 2022 | $23.7 | $19.1 | -19% |
| 2023 | $19.1 | $7.29 | -62% |
| 2024 | $7.29 | $9.53 | +31% |
| 2025 | $9.53 | $10.3 | +7.6% |
| 2026 YTD | $10.3 | $7.87 | -23% |
AHCO's yearly returns have swung widely, from +256% in 2020 to −62% in 2023. It's down 23% so far in 2026.